Rainer R. Kuhn
Basel, BS 4056, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 29, 2018
LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease.
Journal: Journal of Huntington's disease
Published: December 17, 2016
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.
Journal: The Journal of clinical investigation
Published: January 02, 2015
AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.
Journal: Bioorganic & medicinal chemistry
Published: July 14, 2014
Polyglutamine- and temperature-dependent conformational rigidity in mutant huntingtin revealed by immunoassays and circular dichroism spectroscopy.
Journal: PloS one
Published: April 24, 2014
Atg4b-dependent autophagic flux alleviates Huntington's disease progression.
Journal: PloS one
Published: January 23, 2013
Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.
Journal: The Journal of clinical investigation
Published: May 01, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026